Roswell Park Offering CAR T Trial for Autoimmune Conditions
While most CAR T-cell therapies and clinical trials are directed at cancers, a new phase 1 trial at Roswell Park Comprehensive Cancer Center is open and recruiting patients with a variety of autoimmune conditions.
Clinical Scorecard: Roswell Park Offering CAR T Trial for Autoimmune Conditions
At a Glance
Category Detail
Condition Autoimmune Conditions (Systemic Lupus, Lupus Nephritis, Systemic Sclerosis) Key Mechanisms CD20-directed CAR T-cell therapy using gamma-delta T-cells Target Population Patients with refractory autoimmune conditions Care Setting Phase 1 clinical trial at Roswell Park Comprehensive Cancer Center
Key Highlights
Trial aims for deep immune reset and long-term control of autoimmune conditions Unique use of gamma-delta T-cells for targeted therapy Only trial in the U.S. for this specific CAR T-cell product Combination treatment includes chemotherapy followed by CAR T-cell infusion Observed reduction in inflammatory cytokine secretion Guideline-Based Recommendations
Diagnosis
Identify patients with systemic lupus, lupus nephritis, or systemic sclerosis Management
Administer chemotherapy followed by CD20-directed CAR T-cell therapy Monitoring & Follow-up
Evaluate immune response and control of autoimmune symptoms post-infusion Risks
Potential for adverse effects related to CAR T-cell therapy and chemotherapy Patient & Prescribing Data
Individuals with refractory autoimmune conditions
Focus on achieving long-term immune modulation and symptom control
Clinical Best Practices
Ensure thorough patient selection for trial eligibility Monitor patients closely for response and adverse effects Educate patients about the novel treatment approach and its potential benefits References
